Probiotics for Children With Diarrhea
- 1 July 2008
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Clinical Gastroenterology
- Vol. 42 (Supplement), S53-S57
- https://doi.org/10.1097/mcg.0b013e3181674087
Abstract
This review focuses on the efficacy of probiotics for diarrhea in children in different settings: day-care centers, diarrhea acquired in the hospital, antibiotic-associated diarrhea, and treatment of acute infectious diarrhea. For prevention of diarrhea acquired in day-care centers, 5 randomized and placebo-controlled trials have been published. Probiotics tested were Lactobacillus GG, Bifidobacterium lactis (alone or in combination with Streptococcus thermophilus), and Lactobacillus reuteri. The evidence of their efficacy in these settings is only modest: statistically significant for some strains only and in any case of minimal to mild clinical importance. Few trials have examined the potential role of probiotics in preventing the spread of diarrhea in hospitalized children, an event most commonly due to either rotavirus or Clostridium difficile, and they have yielded conflicting results. Overall, these studies provide only weak evidence on the efficacy of probiotics. On the other hand, a large number of trials on the role of probiotics in preventing the onset of antibiotic-associated diarrhea have been published. Most commonly employed probiotics were Lactobacillus GG, Bifidobacterium spp., Streptococcus spp., and the yeast Saccharomyces boulardii. In general, these trials do show clear evidence of efficacy, with the 2 most effective strains being Lactobacillus GG and S. boulardii. Today, we have a large number of published clinical trials on the role of probiotics in treating sporadic infectious diarrhea in children, and many of them are randomized, blinded, and controlled. They consistently show a statistically significant benefit and moderate clinical benefit of a few, well-identified probiotic strains-mostly Lactobacillus GG and S. boulardii, but also L. reuteri-in the treatment of acute watery diarrhea, primarily rotaviral, in infants and young children of developed countries. Such a beneficial effect seems to result in a reduction of diarrhea duration of little more than 1 day, and to be exerted mostly on diarrhea due to rotavirus. The effect is not only strain-dependent, but also dose-dependent, with doses of at least 10 billion/d being necessary.Keywords
This publication has 21 references indexed in Scilit:
- Meta‐analysis: Lactobacillus GG for treating acute diarrhoea in childrenAlimentary Pharmacology & Therapeutics, 2007
- Effect of a Probiotic Infant Formula on Infections in Child Care Centers: Comparison of Two Probiotic AgentsPediatrics, 2005
- Effects of Long-term Consumption of a Fermented Infant Formula (with Bifidobacterium breve c50 and Streptococcus thermophilus 065) on Acute Diarrhea in Healthy InfantsJournal of Pediatric Gastroenterology and Nutrition, 2004
- Acidified Milk Formula Supplemented With Bifidobacterium lactis: Impact on Infant Diarrhea in Residential Care SettingsJournal of Pediatric Gastroenterology and Nutrition, 2004
- Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safetyThe American Journal of Clinical Nutrition, 2004
- Effect of Lactobacillus GG and Breast-feeding in the Prevention of Rotavirus Nosocomial InfectionJournal of Pediatric Gastroenterology and Nutrition, 2002
- Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomisedBMJ, 2001
- Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infantsThe Journal of Pediatrics, 2001
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirusThe Lancet, 1994